Addressing Practical Challenges in HCV Management
Source: Addressing Practical Challenges in HCV Management

Video

Now Playing...
In this on-demand multimedia module combining slides and audio from a live symposium presented at the 2016 annual meeting of the AASLD in Boston, Massachusetts, multidisciplinary expert faulty provide their perspectives on practical aspects of managing patients with HCV, including interpretation of current guidelines and payer policies, approaches to patient engagement in care, specialty pharmacy utilization and navigation of the insurance appeals process, and management of people who inject drugs.

Sherilyn C. Brinkley, MSN, CRNP, has disclosed that she has received funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck and consulting fees from AbbVie and Merck.

Jordan J. Feld, MD, MPH, has disclosed that he has received funds for research support from Abbott, AbbVie, Gilead Sciences, Janssen, Merck, and Regulus and consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Merck.

Jason Grebely, BSc, PhD, has disclosed that he has received funds for research support from AbbVie, Cepheid, Gilead Sciences, and Merck; consulting fees from AbbVie, Gilead Sciences, and Merck; and fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speaker bureaus) from AbbVie, Gilead Sciences, and Merck.

Nancy Reau, MD, FAASLD, AGAF, has disclosed that she has received funds for research support from AbbVie, Gilead Sciences, and Intercept and consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck.

Phoebe Sebhatu, PharmD, BCPS, has disclosed that she has received consulting fees from Bristol-Myers Squibb.

Downloads

  • Addressing Practical Challenges in HCV Management

  • EASL 2017: Emerging Therapies for Genotype 3 HCV

    Nancy Reau MD, FAASLD, AGAF - 5/12/2017    6 comments / Last Comment: 6/23/2017
    Genotype 3 HCV infection is concerning, not just because of its natural history but also because of its potential role in reinfection. New data from EASL offer promise for the treatment of this challenging patient population.
  • How Recent Guideline Updates on HBV Screening in HCV-Infected DAA Recipients Affect Clinical Practice

    Norah Terrault MD, MPH - 11/23/2016    1 comment / Last Comment: 11/29/2016
    How do recent AASLD/IDSA updates on HBV screening change nonspecialist and specialist management of HCV patients? Here’s my take.
  • Do HCV DAAs Increase HCC Recurrence Risk or Not?

    Paul Y. Kwo MD - 5/25/2017    4 comments / Last Comment: 6/14/2017
    Here’s my take on new data from EASL 2017.
  • How Data From the 2016 Boston Hepatology Meeting Will Influence Future HCV Patient Management

    Mark S. Sulkowski MD - 1/31/2017    2 comments / Last Comment: 4/24/2017
    The 2016 hepatology meeting in Boston offered future solutions to some of my most vexing patient challenges.
  • Weighing the Treatment Options for Genotype 3 HCV Infection in Cirrhotics

    Mark S. Sulkowski MD - 2/25/2016    3 comments / Last Comment: 4/11/2016
    In my practice, it is the patient with cirrhosis and genotype 3 HCV infection who causes me to pause and carefully consider the patient’s treatment options.